G01N 2500/04
Screening involving studying the effect of compounds c directly on molecule a
Official title: Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
G01N2500/04 (Screening involving studying the effect of compounds c directly on molecule a) appears on 1,866 US grants and 3,757 published applications in this corpus.
Search patents in G01N- Granted patents
- 1,866
- Published applications
- 3,757
- Assignees
- 1,532
- Inventors
- 7,293
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 2 | 0 |
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 3 | 0 |
| 1997 | 2 | 0 |
| 1998 | 11 | 0 |
| 1999 | 14 | 0 |
| 2000 | 12 | 0 |
| 2001 | 15 | 10 |
| 2002 | 33 | 101 |
| 2003 | 32 | 217 |
| 2004 | 39 | 168 |
| 2005 | 45 | 201 |
| 2006 | 56 | 184 |
| 2007 | 75 | 163 |
| 2008 | 68 | 157 |
| 2009 | 70 | 211 |
| 2010 | 91 | 179 |
| 2011 | 92 | 168 |
| 2012 | 78 | 147 |
| 2013 | 95 | 137 |
| 2014 | 85 | 177 |
| 2015 | 116 | 322 |
| 2016 | 98 | 241 |
| 2017 | 135 | 169 |
| 2018 | 113 | 131 |
| 2019 | 96 | 126 |
| 2020 | 106 | 117 |
| 2021 | 78 | 101 |
| 2022 | 51 | 98 |
| 2023 | 55 | 81 |
| 2024 | 33 | 51 |
| 2025 | 44 | 64 |
| 2026 | 22 | 36 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Molecular profiling of tumors6 Oct 2026US 12,754,193 B2Caris MPI, Inc.
- Multicyclic peptides and methods for their preparation1 Sep 2026US 12,723,059 B2Universiteit Van Amsterdam
- Methods for identification, assessment, prevention, and treatment of metabolic disorders using SLIT211 Aug 2026US 12,702,694 B2Dana-Farber Cancer Institute, Inc.
- Molecular profiling of tumors21 Jul 2026US 12,687,554 B2Caris MPI, Inc.
- Methods and compositions for treating and/or preventing a disease or disorder associated with abnormal level and/or activity of the IFP35 family of proteins16 Jun 2026US 12,655,183 B2Guangzhou Inno-Enmai Biomedical Technology Co., Ltd
- Methods and compositions for displaying peptide libraries8 Oct 2026US 2026/0308224 A1Board of Regents, The University of Texas System
- High throughput optical assay for screening hemoglobin oxygen affinity modifying drug8 Oct 2026US 2026/0309621 A1
- Identifying antibody virus-neutralization status8 Oct 2026US 2026/0309711 A1
- Compositions and methods for determining genetic polymorphisms in the tmem216 gene24 Sep 2026US 2026/0286437 A1The Regents of the University of California
- Methods and compositions for treating and/or preventing a disease or disorder associated with abnormal level and/or activity of the ifp35 family of proteins17 Sep 2026US 2026/0274909 A1Guangzhou Inno-Enmai Biomedical Technology Co., Ltd
Most cited
By later US patents
- Downmodulating an immune response with multivalent antibodies to PD-1309US 6,808,710 B1Dana-Farber Cancer Institute, Inc. · 2004
- Methods for treating diabetic neuropathy258US 7,030,146 B2Kansas University Medical Center · 2006
- Position dependent recognition of GNN nucleotide triplets by zinc fingers216US 7,030,215 B2Sangamo BioSciences, Inc. · 2006
- Isolated polypeptide erbB-3, related to the epidermal growth factor receptor and antibody thereto180US 5,480,968 AThe United States of America as represented by the Department of Health and Human Services · 1996
- PD-1, a receptor for B7-4, and uses therefor156US 7,101,550 B2Dana-Farber Cancer Institute, Inc. · 2006